Biotech company Rigvir Group, which owns a registered oncolytic virotherapy medicine RIGVIR® is looking for partners globally to support and finance the commercialization process of a next generation solution for unmet medical needs in oncology based on the existing product.
We have elaborated collaboration model for early Melanoma and Uveal Melanoma treatment – considering the following:
Clinical studies from 1968
First genetically non-modified virus
One of the fastest growing biotech companies of the Northern Europe
Proven in clinical practice for more than 10 years